Severe hemophilia occurs in less than 1% of
coagulation factor IX activity.
provides general information on
Coagulation Factor IXThe '
Coagulation Factor IX (CAS 9001-28-9) Market Research Report 2010' presents an overview of the
Coagulation Factor IX market globally and regionally, with an analysis of its parameters.
Concentrate osoczopochodnego
coagulation factor IX delivered to the patient~s home / Centre for Treatment of HemophiliaPos.
Contract award notice: the concentrate of recombinant
coagulation factor ix, a minimum of second generation; mark case: zzp-97/16.
Among the programs are those involving Beta Interferon, G-CSF, Parathyroid Hormone, EGF, the various forms of FGF (1 to 22), and pegylated versions of Interferon Alpha, hGH, C-CSF, Beta Interferon, EPO, Coagulation Factor VIII,
Coagulation Factor IX, FGF-1, Interferon Gamma, Interleukin-12, and Insulin-Like Growth Factor-1.
Contract notice: The concentrate of recombinant
coagulation factor ix, a minimum of second generation; mark case: zzp-97/16.
The IND application for the recombinant human
coagulation factor IX program is planned for the end of 2010.
00Lot 5:Human
coagulation factor IX, vials, powder and solventfor solution for injection,500 IUContractor: Ludmila Pharm, LLC, UkraineContracted amount: USD 727,836.
GTC is planning to file IND's for the recombinant human
coagulation factor IX later in 2010.
In the second quarter, GTC received $3 million of a total $6 million funding commitment from LFB Biotechnologies for GTC's share of the 2008 expenses for the collaboration programs in recombinant human coagulation factor VIIa, recombinant human alpha-1 antitrypsin, recombinant human
coagulation factor IX, and a monoclonal antibody to the CD20 human immune receptor.
Lot 2 -
Coagulation Factor IX blood human child (Aimafiks 500 IU or equivalent)
